A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
ConclusionWith a cost-effectiveness threshold of $1550 USD/QALY in Iran, adding linagliptin to insulin is cost-effective in patients with T2DM and moderate CKD. However, for those with mild CKD, it seems that the associated costs outweigh the expected benefits.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insulin | Iran Health | Middle East Health | Study | Urology & Nephrology